Global Single Domain Antibody Library Service Market Strategic Research Report

Scope of the Report

The global Single Domain Antibody Library Service market size is predicted to grow from US$ 181 million in 2025 to US$ 506 million in 2032; it is expected to grow at a CAGR of 15.8% from 2026 to 2032.

Single Domain Antibody Library Service provides high-throughput library construction, screening, discovery, and optimization based on VHH, VNAR, or human VH single-domain antibodies for research, diagnostic, and early drug development customers. The service typically includes library design, phage or yeast display construction, functional screening, affinity maturation, humanization, expression validation, and library management. Key upstream inputs include antigen proteins/peptides, immunized animal resources, natural or synthetic single-domain antibody libraries, display systems, expression vectors, host cells, culture media, chromatography consumables, sequencing and functional assay reagents. Major downstream customers include pharmaceutical companies, biotechnology firms, CRO/CDMO providers, universities, research institutes, and hospital laboratories, applying the service for antibody discovery, candidate drug screening, diagnostic reagent development, molecular imaging, and cell therapy binding domain design. The global gross margin in 2025 is estimated at approximately 55%–75%.

The single-domain antibody library service market is currently in a rapid development phase, driven by growing demand from research institutions, diagnostic companies, and early-stage drug development clients for high-throughput and customized library construction and screening. Service providers deliver comprehensive library discovery and screening solutions through antibody library design, phage or yeast display, functional screening, affinity maturation, humanization, and expression validation. Market participants include CROs specializing in custom research services, platform-based antibody companies, and internal discovery platforms of innovative pharmaceutical companies. Due to their ability to cover complex targets, hidden epitopes, and multispecific candidates, these services are highly valuable in early drug discovery and diagnostic development.

From the supply side, European and North American companies have clear advantages in technology accumulation, library construction, display screening, and humanization capabilities, with some having platform services and libraries available for licensing. Chinese companies have rapidly developed capabilities in VHH, Hu-VHH, and single-domain antibody discovery services, gradually extending from custom research services to early-stage drug development support and platform output. Overall, the market remains fragmented, with leading companies leveraging library quality, complex target screening, engineering experience, and customer service to establish barriers, while smaller providers compete through faster delivery, customization flexibility, and cost efficiency.

Future trends will focus on higher-throughput library construction, AI-assisted antibody screening, multispecific candidate discovery, and automated library management systems. Library services are evolving beyond single antibody discovery to become critical sources of multispecific, engineerable candidates for early-stage drug validation. Integration of deep sequencing, synthetic libraries, machine learning, and automated screening technologies is expected to further improve discovery efficiency and candidate developability. Platforms capable of providing integrated services from library construction and screening to affinity maturation and preliminary expression validation will more easily attract partnerships with pharmaceutical companies and research institutions.

Market growth is primarily driven by the expansion of innovative drug pipelines, increasing demand for complex target development, growth in diagnostic and research applications, and the adoption of AI-assisted antibody discovery technologies. However, the industry faces challenges including platform homogenization, intellectual property barriers, screening success rate limitations, library diversity control, and difficulties in automated management. Some VHH and VNAR molecules derived from non-human species require humanization and safety evaluation before early-stage drug discovery or preclinical research. Furthermore, as more CROs and platform companies enter the library customization field, pricing competition for early-stage services may intensify. Long-term competitive advantage will concentrate in platform companies offering high-quality antibody libraries, complex target screening capabilities, multi-format engineering, and full workflow services.

This report presents a comprehensive overview of the global Single Domain Antibody Library Service market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Immune Library
• Naïve Library
• Synthetic Library
• Other

Segment by Display System

• Phage Display
• Yeast Display
• Other

Segment by Therapeutic Area

• Oncology
• Immunology and Inflammation
• Neurology
• Other

Segment by Application

• Pharmaceutical Companies
• Biotechnology Companies
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Single Domain Antibody Library Service market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Pharmaceutical Companies, Biotechnology Companies, Other evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact